Edition:
United Kingdom

Qiagen NV (QIA.DE)

QIA.DE on Xetra

27.34EUR
4:35pm GMT
Change (% chg)

€0.44 (+1.64%)
Prev Close
€26.90
Open
€27.07
Day's High
€27.41
Day's Low
€26.93
Volume
396,341
Avg. Vol
497,246
52-wk High
€31.52
52-wk Low
€25.41

Latest Key Developments (Source: Significant Developments)

Qiagen to exceed $140 mln of NGS-related sales In 2018
Monday, 8 Jan 2018 

Jan 8 (Reuters) - Qiagen Nv ::SAYS ‍GOAL SET TO EXCEED $140 MILLION OF NGS-RELATED SALES IN 2018, UP FROM OVER $115 MILLION IN 2017​.  Full Article

Qiagen, DiaSorin partner in automated tuberculosis detection
Monday, 8 Jan 2018 

Jan 8 (Reuters) - Qiagen Nv ::SAYS ‍QIAGEN AND DIASORIN PARTNER TO OFFER FULLY AUTOMATED TUBERCULOSIS DETECTION WITH QUANTIFERON-TB GOLD PLUS AVAILABLE ON LIAISON ANALYZER SYSTEMS​.SAYS ‍DIASORIN TO ADD NOVEL CONTENT TO ALREADY BROAD LIAISON MENU, OVER 7,000 SYSTEMS INSTALLED​.SAYS ‍ANNOUNCES MILESTONE OF OVER 40 MILLION QUANTIFERON-TB TESTS SINCE LAUNCH​.  Full Article

Diasorin And Qiagen Partner To Offer Fully Automated Solution For Diagnosis Of Tuberculosis
Monday, 8 Jan 2018 

Jan 8 (Reuters) - DIASORIN SPA ::ANNOUNCES PARTNERSHIP WITH QIAGEN TO OFFER FULLY AUTOMATED SOLUTION FOR DIAGNOSIS OF TUBERCULOSIS.UNDER AGREEMENT, PARTIES ARE DEVELOPING FULLY AUTOMATED VERSION OF QUANTIFERON TEST READ-OUT COMPONENTS.  Full Article

Qiagen To Take Impairment On Deferred Tax Assets
Friday, 22 Dec 2017 

Dec 22 (Reuters) - Qiagen NV ::QIAGEN TO TAKE IMPAIRMENT ON DEFERRED TAX ASSETS, INFORMS ON EXPECTED IMPACTS OF NEW U.S. TAX LAW AND OTHER CHANGES IN GLOBAL TAX ENVIRONMENT.QIAGEN - WILL TAKE AN AFTER-TAX CHARGE ON NET INCOME OF ABOUT $110 MILLION-$120 MILLION (OR ABOUT $0.47-$0.52 PER SHARE) IN Q4.QIAGEN NV - WILL TAKE ADDITIONAL AFTER-TAX CHARGE IN 2018 OF ABOUT $7 MILLION (OR ABOUT $0.03 PER SHARE).  Full Article

‍Qiagen says it ‍will Take Extraordinary After-Tax Charge On Net Income Of About $110-120 mln In Q4 2017 Due To US Tax Reform
Friday, 22 Dec 2017 

Dec 22 (Reuters) - Qiagen Nv ::‍QIAGEN TO TAKE IMPAIRMENT ON DEFERRED TAX ASSETS, INFORMS ON EXPECTED IMPACTS OF NEW U.S. TAX LAW AND OTHER CHANGES IN GLOBAL TAX ENVIRONMENT​.DUE TO US TAX REFORM ‍WILL TAKE EXTRAORDINARY AFTER-TAX CHARGE ON NET INCOME OF ABOUT $110-120 MILLION IN Q4 OF 2017​.WILL ALSO TAKE ‍AN ADDITIONAL EXTRAORDINARY AFTER-TAX CHARGE IN 2018 OF APPROXIMATELY $7 MILLION (OR ABOUT $0.03 PER SHARE)​.‍AS A RESULT, A NEW AFTER-TAX CHARGE OF APPROXIMATELY $10 MILLION IS PLANNED TO BE TAKEN IN Q4 OF 2017​.SAYS ‍DOES NOT EXPECT ANY ADDITIONAL MATERIAL NON-M&A RELATED RESTRUCTURING CHARGES IN 2018​.‍DO NOT AFFECT QIAGEN'S ADJUSTED EPS FORECAST FOR Q4 AND FULL-YEAR 2018.CURRENTLY EXPECTS A PRELIMINARY ADJUSTED TAX RATE FOR FULL-YEAR 2018 OF APPROXIMATELY 20-21%.‍EXTRAORDINARY COSTS WILL BE EXCLUDED FROM ADJUSTED RESULTS​.  Full Article

HTG Molecular Diagnostics And Unit Of QIAGEN Amended First Statement Of Work Under Master Agreement
Wednesday, 20 Dec 2017 

Dec 20 (Reuters) - Htg Molecular Diagnostics Inc ::HTG MOLECULAR DIAGNOSTICS - ON DEC. 18. CO, UNIT OF QIAGEN, AMENDED FIRST STATEMENT OF WORK UNDER MASTER AGREEMENT - SEC FILING.HTG MOLECULAR DIAGNOSTICS - UNDER AGREEMENT, QIAGEN AGREED TO PAY CO LOW, SINGLE‑DIGIT MILLIONS OF DOLLARS FOR NEXT‑PHASE ACTIVITIES FOR PROJECT.  Full Article

Oxford Immunotec And Qiagen Reached A Settlement In Lawsuit
Friday, 15 Dec 2017 

Dec 15 (Reuters) - Oxford Immunotec Global Plc ::OXFORD IMMUNOTEC GLOBAL - CO, QIAGEN REACHED A SETTLEMENT IN LAWSUIT IN U.S. COURT ALLEGING PATENT INFRINGEMENT IN RELATION TO QIAGEN'S PRODUCTS.OXFORD IMMUNOTEC GLOBAL - UNDER TERMS OF AGREEMENT, ALL PENDING CLAIMS BETWEEN OXFORD, QIAGEN AND CO-DEFENDANTS HAVE BEEN RESOLVED.OXFORD IMMUNOTEC GLOBAL - CO GRANTED QIAGEN ROYALTY-FREE, NON-EXCLUSIVE LICENSE THAT EXTENDS TO ALL CURRENT AND FUTURE CUSTOMERS OF QIAGEN'S PRODUCTS.OXFORD IMMUNOTEC GLOBAL PLC - PATENT INFRINGEMENT IS IN RELATION TO QIAGEN'S QUANTIFERON-TB GOLD AND QUANTIFERON-TB GOLD PLUS PRODUCTS.OXFORD IMMUNOTEC GLOBAL PLC - OXFORD GRANTED QIAGEN A ROYALTY-FREE, NON-EXCLUSIVE LICENSE IN EXCHANGE FOR A ONE-TIME, LUMP-SUM PAYMENT OF $27.5 MILLION.  Full Article

Qiagen NV posts qtrly adjusted EPS $0.32‍​
Monday, 6 Nov 2017 

Nov 6 (Reuters) - Qiagen NV :Qiagen NV - qtrly EPS $0.21; qtrly adjusted EPS $0.32‍​.Qiagen NV - reaffirming 2017 adjusted EPS target of $1.25-1.27 cer before restructuring‍​.Qiagen NV - qtrly net sales $364.0 million versus $338.7 mln‍​.Qiagen NV - qtrly adjusted net sales $364.4 million versus $338.7 million.Qiagen NV - for full-year 2017, Qiagen expects adjusted net sales to grow approximately 7 pct cer.Q3 earnings per share view $0.32, revenue view $363.3 million -- Thomson Reuters I/B/E/S.FY2017 earnings per share view $1.18, revenue view $1.42 billion -- Thomson Reuters I/B/E/S.  Full Article

Qiagen to return $250 mln to shareholders
Sunday, 14 Aug 2016 

Qiagen NV :Qiagen announces plans to return approximately $250 million to shareholders via synthetic share repurchase proposal.  Full Article

Qiagen says it intends to return capital of $300 mln to shareholders by 2017 end
Thursday, 28 Jul 2016 

Qiagen Nv : Intends to return capital of $300 million to shareholders by end of 2017 . Intends to return capital to its shareholders in the additional amount of approximately $200 million by early 2017 .Considering share repurchase program announced on 27th April 2016, total return figure is expected to be approximately $300 million.  Full Article

BRIEF-Qiagen NV Receives FDA Clearance For Ipsogen Jak2 RGQ PCR Kit

* QIAGEN NV SAYS RECEIVED CLEARANCE FOR ITS IPSOGEN JAK2 RGQ PCR KIT FROM U.S. FDA FOR ADDITIONAL USE IN DIAGNOSIS OF ALL MYELOPROLIFERATIVE NEOPLASMS Source text for Eikon: Further company coverage: